As of 2026-04-13, the EV/EBITDA ratio of Cue Biopharma Inc (CUE) is 0.03. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CUE's latest enterprise value is -0.64 mil USD. CUE's TTM EBITDA according to its financial statements is -25.56 mil USD. Dividing these 2 quantities gives us the above CUE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.0x - 16.6x | 14.1x |
| Forward P/E multiples | 17.7x - 21.0x | 19.8x |
| Fair Price | (7.80) - (7.26) | (7.45) |
| Upside | -1750.9% - -1637.9% | -1676.6% |
| Date | EV/EBITDA |
| 2026-04-10 | -0.04 |
| 2026-04-09 | 0.41 |
| 2026-04-08 | 0.45 |
| 2026-04-07 | 0.63 |
| 2026-04-06 | 0.66 |
| 2026-04-02 | 0.65 |
| 2026-04-01 | 0.60 |
| 2026-03-31 | 0.54 |
| 2026-03-30 | 0.55 |
| 2026-03-27 | 0.52 |
| 2026-03-26 | 0.50 |
| 2026-03-25 | 0.47 |
| 2026-03-24 | 0.49 |
| 2026-03-23 | 0.47 |
| 2026-03-20 | 0.47 |
| 2026-03-19 | 0.47 |
| 2026-03-18 | 0.47 |
| 2026-03-17 | 0.45 |
| 2026-03-16 | 0.37 |
| 2026-03-13 | 0.43 |
| 2026-03-12 | 0.38 |
| 2026-03-11 | 0.34 |
| 2026-03-10 | 0.37 |
| 2026-03-09 | 0.39 |
| 2026-03-06 | 0.39 |
| 2026-03-05 | 0.42 |
| 2026-03-04 | 0.39 |
| 2026-03-03 | 0.40 |
| 2026-03-02 | 0.43 |
| 2026-02-27 | 0.44 |
| 2026-02-26 | 0.42 |
| 2026-02-25 | 0.43 |
| 2026-02-24 | 0.43 |
| 2026-02-23 | 0.43 |
| 2026-02-20 | 0.43 |
| 2026-02-19 | 0.41 |
| 2026-02-18 | 0.40 |
| 2026-02-17 | 0.41 |
| 2026-02-13 | 0.38 |
| 2026-02-12 | 0.39 |
| 2026-02-11 | 0.35 |
| 2026-02-10 | 0.31 |
| 2026-02-09 | 0.34 |
| 2026-02-06 | 0.35 |
| 2026-02-05 | 0.36 |
| 2026-02-04 | 0.37 |
| 2026-02-03 | 0.33 |
| 2026-02-02 | 0.31 |
| 2026-01-30 | 0.32 |
| 2026-01-29 | 0.26 |